MONDAY, Might well 16, 2022 (HealthDay News) — As the US mourns one million deaths from COVID-19, a brand contemporary study indicates the grim tally could perhaps perhaps additionally had been worse. Employ of the Pfizer-BioNTech COVID-19 vaccine averted greater than 110,000 deaths and 690,000 hospitalizations in the US in 2021, researchers document.
The vaccine additionally averted 8.7 million symptomatic cases of an infection and saved greater than $30 billion in well being care charges and greater than $40 billion in lost productiveness, the study authors illustrious.
“The analyses indicate that the Pfizer-BioNTech COVID-19 vaccine contributed enormous public well being affect in the U.S. in 2021, and had a deep finish on the trajectory of the pandemic,” mentioned Manuela Di Fusco, of Pfizer’s well being economics and outcomes study team.
The Pfizer vaccine used to be the first COVID-19 shot available in the market in the US. It used to be given to simply about six in 10 folks nationwide who were totally vaccinated in 2021, in line with the U.S. Centers for Illness Befriend an eye on and Prevention.
The findings were printed on-line Might well 15 in the Journal of Clinical Economics. The total study authors bought funding from Pfizer both as workers, consultants or workers of companies paid by Pfizer.
Despite the consume of COVID-19 vaccines, the U.S. death toll in the route of the pandemic neared one million final week.
President Joe Biden ordered U.S. flags flown at half of-workers Thursday.
“We must forever stay vigilant by disagreement pandemic and accomplish all the pieces we can to attach as many lives as that it’s seemingly you’ll per chance perhaps perhaps imagine,” Biden mentioned.
On this study, researchers estimated the affect of the Pfizer vaccine using a mannequin, accurate-world data and medical trial data.
The mannequin feeble data on the option of folks vaccinated, the effectiveness of the vaccine in varied age groups, and the potentialities of being contaminated, atmosphere up symptoms and being hospitalized.
It additionally included the consequences of lengthy COVID, the option of working days likely lost as a result of non eternal sickness and the industrial affect of untimely deaths from the disease.
The mannequin didn’t consist of the affect of the extra transmissible Omicron variant that grew to change into the dominant coronavirus stress on the pause of the study period.
The vaccine “used to be estimated to stop tens of millions of COVID-19 symptomatic cases, hundreds of hospitalizations and deaths, and generated billions in societal economic worth in the U.S. in 2021,” Di Fusco mentioned in a journal data liberate.
The findings “highlight the chance to proceed popular vaccination uptake to stop COVID-19-linked disease and generate societal advantages,” she added.
A option of limitations could perhaps perhaps additionally occupy resulted in the numbers in the study being underestimates, in line with Di Fusco and colleagues. These consist of no longer factoring in the vaccine’s seemingly to diminish transmission of the coronavirus, the severity of cases and the overall affect of lengthy COVID .
The researchers additionally illustrious that their findings can’t be utilized to other COVID-19 vaccines or groups of folks no longer namely analyzed in the study.
There is extra on COVID-19 vaccines on the U.S. Centers for Illness Befriend an eye on and Prevention.
SOURCE: Journal of Clinical Economics, data liberate, Might well 16, 2022